DUALNANOTHER

Dual cancer nanotherapies combining magnetic and plasmonic hyperthermia

Coordinatore	UNIVERSITE PARIS DIDEROT - PARIS 7    more  Organization address address: RUE THOMAS MANN 5 city: PARIS postcode: 75205 contact info Titolo: Ms. Nome: Eleonora Cognome: Zuolo Email: send email Telefono: +33 1 57276593
Nazionalità Coordinatore	France [FR]
Totale costo	194˙046 €
EC contributo	194˙046 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IEF
Funding Scheme	MC-IEF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-04-01   -   2016-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITE PARIS DIDEROT - PARIS 7  Organization address address: RUE THOMAS MANN 5 city: PARIS postcode: 75205 contact info Titolo: Ms. Nome: Eleonora Cognome: Zuolo Email: send email Telefono: +33 1 57276593	FR (PARIS)	coordinator	194˙046.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This project is designed to provide answers to questions not yet covered in the literature regarding hyperthermia cancer therapy based on the activation of magnetic and/or plasmonic nanomaterials. It aims at understanding and measuring nanoparticle-based heat-generating potential in environments that gradually approach the in vivo situation. The originality of the approach proposed is to combine in-depth physical studies (magnetic, plasmonic) of nanomaterials in biological environment while exploring new therapeutic modalities. Two main issues will be addressed: (1) the influence of magnetic or plasmonic nanoparticle confinement inside cells on heat-generating potential; (2) the possible synergism between magnetic and plasmonic hyperthermia, with a view to combined therapy, and their cumulative efficacy in solution, in vitro cell models, and in vivo tumour models. These issues will be addressed at several levels, ranging from materials chemistry to antitumoral applications in living animals, by exploiting multiple disciplines. To open the way to new therapeutic tools, it will be necessary to test a wide variety of nanoparticles with different compositions, shapes and sizes, provided by leading teams in nanomaterials synthesis, as well as to develop appropriate nanometrologic methods to detect, quantify and characterize the different nanostructures in their biological environment.'